Assessment of clinical outcomes in patients with fibromyalgia: Analysis from the UK Medical Cannabis Registry
Claire Wang, Simon Erridge, Carl Holvey, Ross Coomber, Azfer Usmani, Mohammed Sajad, Rahul Guru, Wendy Holden, James J. Rucker, Michael W. Platt, Mikael H. Sodergren
Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.; Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.; Sapphire Medical Clinics, London, UK.; Sapphire Medical Clinics, London, UK.; Sapphire Medical Clinics, London, UK.; St. George’s Hospital NHS Trust, London, UK.; Sapphire Medical Clinics, London, UK.; Department of Psychological Medicine, Kings College London, London, UK.; South London & Maudsley NHS Foundation Trust, London, UK. |
Affiliationer
Methods
: Patients treated with CBMPs for a minimum of 1 month were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in validated patient-reported outcome measures (PROMs). A p-value of <.050 was deemed statistically significant.
Results
: In total, 306 patients with fibromyalgia were included for analysis. There were improvements in global health-related quality of life at 1, 3, 6, and 12 months (p < .0001). The most frequent adverse events were fatigue (n = 75; 24.51%), dry mouth (n = 69; 22.55%), concentration impairment (n = 66; 21.57%), and lethargy (n = 65; 21.24%).
Conclusion
: CBMP treatment was associated with improvements in fibromyalgia-specific symptoms, in addition to sleep, anxiety, and health-related quality of life. Those who reported prior cannabis use appeared to have a greater response. CBMPs were generally well-tolerated. These results must be interpreted within the limitations of study design.